Skip to Content

Abraxane Approval History

  • FDA approved: Yes (First approved January 7th, 2005)
  • Brand name: Abraxane
  • Generic name: paclitaxel protein-bound
  • Dosage form: for Injectable Suspension
  • Company: American Pharmaceutical Partners, Inc. / American Bioscience, Inc.
  • Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer

Abraxane (paclitaxel protein-bound) is an albumin-bound form of the antineoplastic agent paclitaxel indicated for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.

Development History and FDA Approval Process for Abraxane

DateArticle
Sep  6, 2013Approval FDA Approves Abraxane for Late-Stage Pancreatic Cancer
Oct 12, 2012Approval FDA Approves Abraxane for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Jan  7, 2005Approval Abraxane American Pharmaceutical Partners, Inc. / American Bioscience, Inc. - Treatment for Metastatic Breast Cancer
May 10, 2004American Pharmaceutical Partners and American BioScience Announce FDA Acceptance of New Drug Application of Abraxane for the Treatment of Metastatic Breast Cancer
Mar  8, 2004American Pharmaceutical Partners and American BioScience Announce Filing of a New Drug Application for FDA Approval of Abraxane for the Treatment of Metastatic Breast Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide